Early first-in-human data at AACR 2026 pointed to a novel CAR T architecture designed to reduce chronic activation stress in solid tumors. Perelman School of Medicine investigators presented Phase I results for SynKIR-110, a KIR-CAR T concept using a multi-chain, “on-off” assembly strategy modeled after natural killer receptors. In a small dose-escalation trial enrolling nine patients with mesothelin-expressing cancers, researchers reported a favorable safety profile and early efficacy signals including disease stabilization and an ongoing partial response in the highest dose cohort. The approach aims to address T-cell exhaustion by keeping engineered cells in a resting state until target engagement. While still early, the data add to the growing design space for next-generation cell therapies targeting solid tumors where durable responses have been harder to achieve.